C
Claire Hemmaway
Researcher at The Queen's Medical Center
Publications - 35
Citations - 1108
Claire Hemmaway is an academic researcher from The Queen's Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 26 publications receiving 764 citations. Previous affiliations of Claire Hemmaway include Auckland City Hospital.
Papers
More filters
Journal ArticleDOI
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Valter Torri,Christopher P. Fox,Paul La Rosée,Elisabeth Schorb,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Angela Ferrari,Kim Linton,Roberta Rudà,Mascha Binder,Tobias Pukrop,Monica Balzarotti,Alberto Fabbri,Peter Johnson,Jette Sønderskov Gørløv,Georg Hess,Jens Panse,Francesco Pisani,Alessandra Tucci,Stephan Stilgenbauer,Bernd Hertenstein,Ulrich Keller,Stefan W. Krause,Alessandro Levis,Hans J. Schmoll,Franco Cavalli,Jürgen Finke,Michele Reni,Emanuele Zucca,Gerald Illerhaus +36 more
TL;DR: The IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials.
Journal ArticleDOI
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Andrés José Maria Ferreri,Kate Cwynarski,Elisa Jacobsen Pulczynski,Christopher P. Fox,Elisabeth Schorb,Paul La Rosée,Mascha Binder,Alberto Fabbri,Valter Torri,Eleonora Minacapelli,Monica Falautano,Fiorella Ilariucci,Achille Ambrosetti,Alexander Röth,Claire Hemmaway,Peter Johnson,Kim Linton,Tobias Pukrop,Jette Sønderskov Gørløv,Monica Balzarotti,Georg Hess,Ulrich Keller,Stephan Stilgenbauer,Jens Panse,Alessandra Tucci,Lorella Orsucci,Francesco Pisani,Alessandro Levis,Stefan W. Krause,Hans J. Schmoll,Bernd Hertenstein,Mathias J. Rummel,Jeffery Smith,Michael Pfreundschuh,Giuseppina Cabras,Francesco Angrilli,Maurilio Ponzoni,Martina Deckert,Letterio S. Politi,Juergen Finke,Michele Reni,Franco Cavalli,Emanuele Zucca,Gerald Illerhaus +43 more
TL;DR: The results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT) as an alternative to whole-brain radiotherapy (WBRT) as consolidation after high-dose-methotrexate-based chemoimmunotherapy were reported.
Journal ArticleDOI
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma
Christopher P. Fox,Elizabeth H Phillips,Jeffery Smith,Kim Linton,Eve Gallop-Evans,Claire Hemmaway,Dorothee P. Auer,Charlotte Fuller,Andrew Davies,Pamela McKay,Kate Cwynarski +10 more
TL;DR: This book aims to provide a history of haematology and clinical practice in the field in the context of regenerative medicine and its role in cancer treatment.
Journal ArticleDOI
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease
Jo Howard,Jo Howard,Claire Hemmaway,Paul Telfer,D. Mark Layton,John B. Porter,Moji Awogbade,Timothy Mant,Timothy Mant,Daniel D. Gretler,Kobina Dufu,Athiwat Hutchaleelaha,Mira Patel,Vincent Siu,Sandra V. Dixon,Noel Landsman,Margaret Tonda,Joshua Lehrer-Graiwer +17 more
TL;DR: All patients who received multiple doses of voxelotor for ≥28 days experienced hematologic improvements including increased Hb and reduction in hemolysis and percentage of sickled red cells, supporting the potential of v oxelotor to serve as a disease-modifying therapy for SCD.
Journal ArticleDOI
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Michael Dennis,Nigel H. Russell,Robert Kerrin Hills,Claire Hemmaway,Nicki Panoskaltsis,Mary Frances McMullin,Lars Kjeldsen,Helen Dignum,Ian Thomas,Richard E. Clark,Don Milligan,Alan K. Burnett +11 more
TL;DR: Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial in older patients with relapsed/refractory disease, and in vitro data suggested synergy with cytarabine (Ara-C).